The targeted sequencing and resequencing market — next-generation sequencing (NGS) workflows that focus on a defined, clinically relevant set of genes or genomic regions rather than sequencing an entire genome or exome — has become the dominant NGS technology segment in clinical oncology, with the Targeted Sequencing And Resequencing Market reflecting the segment's roughly 70-72% share of the broader clinical oncology NGS market as of recent industry estimates. Cost and turnaround-time efficiency — targeted panels analyze a fraction of the data volume required for whole-genome or whole-exome sequencing, translating into lower per-sample cost, faster turnaround, and reduced downstream bioinformatics burden — is the primary driver behind pathologist and clinical-lab preference for focused panels over broader sequencing approaches in routine tumor profiling. Clinical guideline alignment is accelerating adoption: treatment guidelines across breast, lung, and hematologic malignancies increasingly require concurrent analysis of multiple actionable genes rather than sequential single-marker testing, prompting labs to replace older single-gene assays with pan-cancer targeted panels such as FoundationOne CDx and Oncomine. Regulatory clarity is also fueling uptake — the FDA's 2024 classification of NGS tumor-profiling assays as Class II devices clarified validation pathways for lab developers, reducing regulatory ambiguity that had previously slowed clinical adoption. Commercial platform innovation from major players — Illumina's gene panel and array-based targeted resequencing offerings, Pacific Biosciences' Sequel System for long-read targeted sequencing, and QIAGEN's upgraded CLC Genomics Workbench software for faster somatic variant analysis — demonstrates how both instrument makers and software vendors are competing to capture value across the targeted sequencing workflow. Expansion beyond oncology into liquid biopsy, rare-disease diagnostics, reproductive genetic testing (including non-invasive prenatal testing and preimplantation genetic testing), and infectious-disease surveillance is broadening the addressable market well beyond traditional solid-tumor and hematologic malignancy testing.

Do you think targeted panels will keep their dominant share as sequencing costs continue to fall, or will whole-genome sequencing's faster cost decline eventually make broader, less-targeted approaches the more practical clinical default?

FAQ

Why do most clinical oncology labs prefer targeted sequencing over whole-genome or whole-exome sequencing? Targeted panels focus computational and financial resources on a curated set of genes with known, actionable associations to specific cancers, which lowers the cost per sample, shortens turnaround time, and simplifies the bioinformatics needed to generate an interpretable clinical report. Because oncologists need clear, actionable results to guide therapy selection rather than exhaustive genomic data, targeted panels have become the preferred choice for a large majority of cancer patients undergoing molecular profiling, particularly in breast, lung, and hematologic malignancies where multi-gene, guideline-driven testing is now standard practice. Whole-genome sequencing remains valuable for uncovering rare or structural variants not captured by fixed gene panels, but its higher cost and data burden currently limit it to more specialized or research-driven use cases.

What technologies and applications make up the targeted sequencing and resequencing segment? The segment is generally segmented by technology into hybrid-capture sequencing, amplicon sequencing, CRISPR-based enrichment, and molecular inversion probes, by sample type into DNA and RNA-based workflows, and by application across oncology, rare-disease diagnostics, reproductive genetic testing, and infectious-disease surveillance. End users span academic and research institutes, hospitals, diagnostic laboratories, and pharmaceutical/biotech companies conducting companion-diagnostic development. Leading commercial platforms include Illumina's targeted resequencing panels and array finder tools, Pacific Biosciences' long-read Sequel System, and Agilent's SureSelect Cancer CGP Assay, alongside software tools like QIAGEN's CLC Genomics Workbench for converting raw sequencing data into clinically interpretable variant reports.

#TargetedSequencing #NGS #NextGenSequencing #PrecisionOncology #GenomicsMarket #CancerDiagnostics #LiquidBiopsy